tumors and in tumors treated with cytotoxic anticancer agents In the last decade, basic cancer research has produced (3) . Together, these observations suggested that apoptosis remarkable advances in our understanding of cancer biocontributed to the high rate of cell loss in malignant tumors logy and cancer genetics. Among the most important of and, moreover, could promote tumor progression. Nevertheless, these advances is the realization that apoptosis and the the importance of apoptosis in cancer remained under-apprecigenes that control it have a profound effect on the malignant ated for Ͼ15 years. phenotype. For example, it is now clear that some oncogenic mutations disrupt apoptosis, leading to tumor initiation, Apoptosis and tumorigenesis progression or metastasis. Conversely, compelling evidence indicates that other oncogenic changes promote apoptosis,
The cloning and characterization of the bcl-2 oncogene estabthereby producing selective pressure to override apoptosis lished the importance of apoptosis in tumor development. bclduring multistage carcinogenesis. Finally, it is now well 2 was first identified at the chromosomal breakpoint of t(14; documented that most cytotoxic anticancer agents induce 18) in a human leukemia line and was later shown to be a apoptosis, raising the intriguing possibility that defects in common event in follicular lymphoma (5, 6) . At this time, apoptotic programs contribute to treatment failure.
oncogenes were classified as either 'transforming' or 'immorBecause the same mutations that suppress apoptosis during talizing' oncogenes based on their properties in rodent cell tumor development also reduce treatment sensitivity, transformation assays. However, bcl-2 did not behave like a apoptosis provides a conceptual framework to link cancer typical oncogene: instead of disrupting normal proliferation genetics with cancer therapy. An intense research effort is controls, Bcl-2 promoted cell survival by blocking programmed uncovering the underlying mechanisms of apoptosis such cell death (7) (8) (9) . Moreover, in transgenic mice, Bcl-2 overexprthat, in the next decade, one envisions that this information ession promoted lymphoproliferation and accelerated c-Mycwill produce new strategies to exploit apoptosis for therainduced lymphomagenesis (8, 10) . To date, at least 15 Bcl-2 peutic benefit. family member proteins have been identified in mammalian cells, including proteins that promote apoptosis and those that prevent apoptosis (11) . In addition to Bcl-2, Bcl-x L is a potent Introduction death suppressor that is upregulated in some tumor types (12) . Conversely, Bax is a death promoter that is inactivated in Apoptosis was initially described by its morphological characcertain types of colon cancer and in hematopoietic malignancteristics, including cell shrinkage, membrane blebbing, chroies (13, 14) . matin condensation and nuclear fragmentation (1) (2) (3) . The p53 was the first tumor suppressor gene linked to apoptosis. realization that apoptosis is a gene-directed program has had p53 mutations occur in the majority of human tumors and are profound implications for our understanding of developmental often associated with advanced tumor stage and poor patient biology and tissue homeostasis, for it implies that cell numbers prognosis (15) . By 1992, p53 was clearly established as a can be regulated by factors that influence cell survival as well checkpoint protein involved in cell-cycle arrest and maintaining as those that control proliferation and differentiation. Moreover, genomic integrity following DNA damage. However, p53 the genetic basis for apoptosis implies that cell death, like any could induce apoptosis when overexpressed in a myeloid other metabolic or developmental program, can be disrupted leukemia cell line, suggesting that p53 might also regulate cell by mutation. In fact, defects in apoptotic pathways are now survival (16) . Studies using p53 knockout mice demonstrated thought to contribute to a number of human diseases, ranging that endogenous p53 could participate in apoptosis: p53 was from neurodegenerative disorders to malignancy (4) . required for radiation-induced cell death in the thymus, but The notion that apoptosis might influence the malignant not cell death induced by glucocorticoids or other apoptotic phenotype goes back to the early 1970s. Kinetic studies of stimuli (17, 18) . Hence, the role of p53 in apoptosis was tumor growth implied that cell loss from tumors could be indirectly linked to DNA damage and could be stimulusmassive; indeed, observed tumor growth rates could be Ͻ5%
(radiation) and tissue-specific (thymocytes). It is now known of that predicted from proliferation measurements alone (1, 2) . that other stimuli can activate p53 to promote apoptosis, In principle, changes in this 'cell loss factor' could have a including hypoxia and mitogenic oncogenes (see below). major impact on tumor growth or regression. Although most Moreover, several upstream and downstream components of the p53 pathway (e.g. Mdm-2, ARF and Bax) are mutated in the importance of apoptosis in carcinogenesis, it is now example, IGF-1 promotes cell survival through the PI-3 kinase pathway (34) , and depletion of IGF-1 or other survival factors clear that mutations in many cancer-related genes can disrupt apoptosis. For example, the Fas/CD95 receptor normally concan trigger 'death by default' (35) . In contrast, other stimuli involve true pro-apoptotic factors; as an example, many forms trols cell numbers in the immune system by eliminating cells through apoptosis, and disruption of this pathway can lead to of cellular stress can activate p53, which promotes apoptosis through pro-apoptotic molecules like Bax (25, 28, 36) . lymphoproliferative disorders and even cancers (19). In addition, several signal transduction pathways promote cell survival
The identification of apoptotic 'triggers' provides insight into the forces of tumor evolution (see also next section). For in response to growth and/or survival factors, and these pathways may be crucial in controlling cell numbers in vivo.
example, in the skin, excessive exposure to UV radiation induces apoptosis, which presumably serves to eliminate heavOne critical pathway involves signaling through PI-3 kinase (20) , which can be activated by Ras and is downregulated by ily damaged cells. UV radiation induces apoptosis, and loss of p53 function leads to the survival of these damaged cells the PTEN tumor suppressor (21). Ras activation and PTEN loss are common in human tumors.
thereby initiating tumor development (37). Other apoptotic triggers are important in tumor progression. As developing Studies using transgenic and knockout mice provide direct evidence that disruption of apoptosis can promote tumor tumors outgrow their blood supply, they encounter hypoxia (low oxygen), which can activate p53 to promote apoptosis development. In addition to the lymphomas (10), bcl-2 transgenes accelerate SV40 large T antigen-induced mammary (38). Cells acquiring apoptosis defects (e.g. p53 mutations) can survive hypoxic stress, leading to their clonal expansion carcinogenesis (22) . Similarly, p53 loss produced by gene 'knockout' accelerates tumor progression in many settings, within the tumor (38). Similarly, as developing tumor cells undergo repeated divisions, telomeres are shortened until some including the murine retina, lens, choroid plexus and in the lymphoid compartment (23) . In many cases, p53 loss is malfunction triggers either senescence or apoptosis. Like hypoxia, p53 is required for apoptosis induced by telomere associated with reduced apoptosis in situ. Additionally, mouse studies reveal the crucial role of extracellular survival factors malfunction; thus p53 mutant cells survive this response and are genomically unstable (39) . Indeed, suppression of the in supporting tumor progression. For example, large T antigeninduced pancreatic tumors require the upregulation of apoptotic response to telomere malfunction may explain why combined loss of telomerase and p53 stimulates tumor developinsulin-like growth factor 2 (IGF-2) for progression to carcinomas-in fact, tumors arising in IGF-2 animals remain ment (40). These studies may explain why p53 mutations are usually late events in tumor development-a cell acquiring a hyperplastic and display excessive apoptosis (24). Moreover, inactivation of PTEN promotes tumorigenesis and cell survival p53 mutation might not have a selective advantage until the developing tumor encounters hypoxic conditions or achieves when disrupted in mice (21), and disruption of the pro-apoptotic bax gene accelerates brain and mammary tumorigenesis in sufficient telomere erosion. Disruption of apoptosis may also contribute to tumor metalarge T antigen transgenic mice (25, 26) .
Because molecules that regulate apoptosis can have other stasis. To metastasize, a tumor cell must acquire the ability to survive in the bloodstream and invade a foreign tissue. Normactivities, it is often difficult to demonstrate that mutations in tumors actually confer a survival advantage. For example, p53 ally, this process is prevented by the propensity of epithelial cells to die in suspension, or in the absence of the appropriate can promote apoptosis, cell-cycle arrest and senescence such that loss of p53 function increases viability, chromosomal tissue survival (41). Clearly, the fact that these processes trigger apoptosis creates selective pressure to mutate apoptotic instability and cellular lifespan. However, compelling evidence indicates its apoptotic activity is important in tumor suppresprograms during tumor development. Apoptosis in suspension is controlled by a number of other molecules, including the sion. First, marked decreases in apoptosis correlate with the occurrence of p53 mutations in some transgenic mice (23) and focal adhesion kinase and signal transduction pathways (42) . Some studies argue that p53 and Bcl-2 can also influence cell in clonal progression of Wilms' tumor (27). Second, disruption of several p53 effectors in apoptosis (e.g. bax, apaf-1 and death in suspension (43), and others observe enrichment for p53 mutations or Bcl-2 overexpression in metastases (44, 45) . casp-9) can promote oncogenic transformation and tumor development in mouse model systems (25, 28, 29) . In colon Hence, loss of apoptosis can impact tumor initiation, progression and metastasis. cancer, bax and p53 mutations appear mutually exclusive, consistent with a pathway relationship (30). In contrast, p21, which is essential for p53-mediated arrest, is rarely mutated Mechanisms of apoptosis in human tumors (31). Finally, some tumor-derived p53 mutants remain capable of promoting cell-cycle arrest while losing Although the primary focus of this review is on the biology of apoptosis in cancer, much is known about the biochemical their apoptotic potential (32,33). Nevertheless, these data do not imply that the other p53 activities are dispensible for tumor action of many apoptotic players, and key components are being assembled into pathways. At the molecular level, the suppression; rather, they simply argue that its apoptotic activity is important.
best understood cell death pathways involve those initiated by 'death receptors', including Fas/CD95, TNFR1, DR3, DR4 What triggers apoptosis during tumor development? A variety of signals appear important. Extracellular triggers and DR5 (46). Upon binding, tumor necrosis factor α (TNF-α) trimerizes its ligand TNFR1 and results in the subsequent include growth/survival factor depletion, hypoxia, radiation and loss of cell-matrix interactions. Internal imbalances can recruitment of the signal transducing molecules TRADD through conserved protein interaction regions known as 'death also trigger apoptosis, including DNA damage (produced by cell-cycle checkpoint defects or exogenous toxins), telomere domains'. TRADD recruits RIP and TNF receptor-associated factor (TRAF-2), leading to activation of nuclear factor κB malfunction and inappropriate proliferative signals produced by oncogenic mutations. In some instances the apoptotic (NF-κB), which suppresses TNF-α-induced apoptosis (47).
While the recruitment of FADD by TRADD results in apoptosis 'trigger' actually alleviates an anti-apoptotic signal. For through activation of a cell death protease, caspase-8. Activated apoptosis results from a complex integration of internal and external pro-and anti-apoptotic signals. caspase-8 initiates a protease cascade that cleaves cellular Apoptotic programs cannot simply be described as two targets and results in apoptotic cell death (46). Hence, disrupparallel programs converging on a common caspase machinery. tion of FADD can prevent activation of caspase-8, thereby
First, genetic studies using caspase-deficient mice demonstrate producing defects in receptor-mediated cell death (48). This that the requirement for different death effector molecules pathway is rarely the target of oncogenic mutations, but, if during apoptosis is highly variable, being cell-type and stimulus anything, it is enhanced during tumor development (see below).
specific (61) (62) (63) (64) (65) . Second, a large degree of 'cross-talk' can Growth factors, cytokines and DNA damage appear to signal exist between pathways. For example, p53 can transactivate cell death through the mitochondria, and this pathway is the genes encoding death receptors (73) . Also, receptor-mediated target of many oncogenic mutations. These diverse signals activation of caspase-8 can cleave and activate BID, a proaffect the function of Bcl-2 family members which, in turn, can apoptotic Bcl-2 family member that can facilitate cytochrome modulate the mitochondrial function though the permeability c release from the mitochondria (74, 75) . Animal studies transition pore (PTP), a proposed channel evolved in mitochonindicate that the caspase-8/BID pathway is highly cell-type dria following necrotic or apoptotic signals. The PTP is thought dependent (76). It is likely that more complexities will be to be composed of clustered components of the mitochondrial identified; although confounding to the experimentalist, cell membranes, including the voltage-dependent anion channel type and stimuli specificities provide avenues for designing and adenine nucleotide translocator; and the opening of PTP selective therapeutics. results in the release of cytochrome c from mitochondria (49). Consistent with this idea, the crystal structure of Bcl-x L is reminiscent of pore-forming proteins of some bacterial toxins Oncogenic mutations can promote apoptosis (50) . Enforced expression of the pro-apoptotic molecules Bax Some oncogenic changes promote, rather than suppress or Bak can result in increased mitochondria membrane potential apoptosis. Although this finding has ramifications for multistep and release of cytochrome c, which can be blocked by carcinogenesis and cancer therapy (see below), the initial overexpression of Bcl-2 (51). Cytosolic cytochrome c can insights came from studies on adenovirus. Adenovirus encodes interact with Apaf-1 and pro-caspase-9 to initiate a protease several oncoproteins that, when expressed together, transform cascade similar to that described above (52) (53) (54) . rodent cells (77). The E1A oncoprotein induces quiescent cells As eluded to above, a series of enzymes known as caspases to enter S phase (presumably to make the host cell permissive are considered the engine of apoptotic cell death. Caspases for virus replication) and, as a result, acts as a potent oncogene. are cysteine proteases that are expressed as inactive proThe E1B 19 and 55K oncoproteins are required for efficient enzymes, and can be broadly classified into 'signaling' or virus replication and cooperate with E1A in transformation. 'effector' caspases (55). Signaling pro-caspases associate with Adenovirus mutants lacking the E1B 19K protein induce an specific adapter molecules that facilitate caspase activation by E1A-dependent 'cytocidal' phenotype that is associated with induced proximity (56) (57) (58) . For example, caspase-9 associates 'degradation' of both viral and host-cell DNA (78, 79) . As a with Apaf-1, and oligomerization of this complex in the result, E1B mutant adenoviruses produce poor virus yield. presence of cytochrome c can activate the downstream caspase Subsequent studies explained these puzzling observation: E1A cascade. Other adapter/caspase complexes include FADD/ induces apoptosis, and the E1B 19K oncoprotein acts like Bclcaspase-8 and RAIDD/caspase-2 (46). In mitochondrial path-2 to suppresses apoptosis (80). In virus-infected cells, E1B ways, most caspases act downstream of cytochrome c release, prevents E1A-induced apoptosis, allowing viral replication to and some evidence suggests that disruption of caspases only proceed. This implies that apoptosis can act to counter virus delays cell death (59,60). However, in other circumstances, replication and provides a biologic basis for cooperation loss of these proteases produces pathological increases in between E1A and E1B in adenovirus transformation. cell numbers (29, [61] [62] [63] [64] [65] . To date, little is known about the Studies on the c-myc oncogene highlight the importance of involvement of caspase mutations in cancers. Nevertheless, oncogene-induced apoptosis in human cancer (81) . In normal disruption of Apaf-1 is associated with Noonan's Syndrome, cells, ectopic c-Myc expression drives proliferation and precaspase-10 mutations contribute to autoimmune lymphoprolifvents cell-cycle arrest upon serum withdrawal. However, while erative syndrome type II (65, 66) , and frameshift mutations in c-Myc-expressing cells continue to proliferate in low serum, caspase-5 can occur in hereditary nonpolyposis colorectal cells do not accumulate because they die by apoptosis (82). cancers, gastrointestinal and endometrial tumors (67) .
Importantly, survival factors such as IGF-1 can suppress cCertain signal transduction pathways alter the probability Myc-induced cell death without producing substantial effects with which pro-apoptotic signals induce apoptosis. For on c-Myc-induced proliferation (83). The observation that cexample, cytokines such as IL-6 can suppress p53-induced Myc actively promotes apoptosis explains the potent apoptosis in certain cell types (16) . Also, TNF-α-induced cooperative effects observed between c-myc and bcl-2 in apoptosis is modulated by TRADD's ability to bind TRAF2, murine lymphomagenesis (10). In fact, much like E1A and which facilitates NF-κB-mediated cell survival (47,68). Finally, E1B, c-Myc cooperates with Bcl-2 to transform rodent PI-3 kinase pathway mediates cell survival signaling from fibroblasts (84,85). The ability of c-Myc to cooperate with extracellular cytokines receptors. These receptors activate Ras Bcl-2 in transformation could be viewed very much like E1A and a kinase cascade involving PI-3 kinase and Akt leading to and E1B; Bcl-2 allows c-Myc-induced proliferation to proceed the ultimate phosphorylation and inactivation of pro-apoptotic without apoptosis. molecules such as BAD and caspase-9 (69,70). PTEN acts as Why do some oncogenes promote apoptosis? Studies on ca lipid phosphatase to inactivate 3-phosphorylated phosphoinoMyc have been unable to separate its proliferative functions sitides, thereby downregulating this pathway (71,72). Together, from those which promote apoptosis, implying that the processes are coupled (86). Similarly, in normal fibroblasts, the these studies imply that the ultimate decision to initiate ability of E1A to promote apoptosis depends on its ability to inactivate the retinoblastoma tumor suppressor, and cannot be separated from its transforming functions (87). However, Rb loss leads to increased apoptosis in animal models (88,89), and reintroduction of Rb into cells lacking functional protein can suppress apoptosis (90). Both E1A and loss of Rb deregulate the E2F transcription factors, and E2F-1 overexpression itself can induce apoptosis (91) (92) (93) . Hence, the pro-apoptotic activities of E1A and c-Myc appear directly or indirectly coupled to their hyperproliferative activity, implying that apoptosis acts as part of a cellular fail-safe mechanism to limit the consequences of aberrant mitogenic signaling.
The edent mechanism. Hence, oncogenes can induce apoptosis in both p53-dependent and -independent manners, depending on cellular context. as well as active induction of cell death in oncogene-expressing Recent studies indicate that p19 ARF acts as an essential cells ( Figure 1 ). intermediate in oncogene signaling to p53 (103) . For example, Caspase-9 and its adapter Apaf-1 are essential downstream oncogenes such as E1A or c-myc induce ARF message and components of p53 in oncogene-induced death (29). Hence, protein in normal mouse embryo fibroblasts, which correlates disruption of either Apaf-1 or caspase-9 in fibroblasts prevents c-Myc-induced death without affecting p53 accumulation or with their ability to activate p53 and promote apoptosis.
activation. In fact, inactivation of either caspase-9 or apaf-1 Recently, ARF was shown to be a transcriptional target of completely substitutes for p53 loss in promoting the oncogenic c-Myc (104). In contrast, these oncogenes fail to activate p53 transformation of cells by c-Myc and Ras (29). Concordantly, in ARF-null cells, and promote proliferation without substantial Apaf-1 has been identified in cell free systems as an 'oncogeneapoptosis (105, 106) . Together, these studies indicate that generated activity' important for apoptosis in E1A-expressing p19 ARF acts as part of a p53-dependent fail-safe mechanism cells (107,111). Because cytochrome c is an essential co-factor to counter hyperproliferative signals, and predict that disruption that is required for activation of the Apaf-1/caspase-9 protease of ARF, or the INK4a/ARF locus, should cooperate with complex, these studies suggest how oncogenes are linked to mitogenic oncogenes during tumor development. Studies using the effector phase of apoptosis ( Figure 1 ). Of note, several c-myc transgenic mice support this view (102) .
molecules that modulate oncogene-induced apoptosis are mutOne question is whether oncogenes directly induce apoptosis ated in human tumors, and the data described above identify or 'sensitize' the cell to various apoptotic stimuli. Clearly, Apaf-1 and caspase-9 as candidate tumor suppressors (Figure oncogenes can induce apoptosis directly if expressed at suffi-1). However, to date, no mutations in either apaf-1 or caspasecient levels, and E1A-expressing cells possess an oncogene-9 have been described. Perhaps these components act too late generated activity capable of activating apoptosis in cell free in the cell death program to provide a long-term survival systems (107). However, cells stably expressing E1A or cadvantage; alternatively, the mutational status of these genes Myc are 'sensitized' to diverse apoptotic stimuli, including may not have been thoroughly examined. serum depletion, DNA damaging agents, hypoxia, Fas, TNF-α and other stimuli (81) . One target of oncogene-induced Apoptosis and cancer therapy sensitization is the mitochondria. Both E1A and c-Myc facilitate cytochrome c release from mitochondria, and cytochrome
Most anticancer agents now in use were developed using c alone is sufficient to sensitize cells to diverse agents empirical screens designed to identify agents that selectively (107,108). Oncogenes can facilitate cytochrome c release kill tumor cells. Until recently, most research into drug action independently of p53 (108) , although it is worth noting that focused on their intracellular targets, the nature of the cellular p53 can induce Bax and proteins that affect mitochondrial damage produced by the drug-target interaction, or resistance mechanisms that prevent the drug target interaction. However, function (109,110). Hence, p53 may be involved in sensitization treatment sensitivity in carcinomas is less clear: whereas some studies identify striking correlations between p53 mutations and poor treatment response, others see no effect (116, 128) . Few studies have associated Bcl-2 with drug resistance in patients and, in fact, high Bcl-2 levels may be a good prognostic indicator for breast cancer. Finally, in some settings loss of Bcl-2 and p53 delays therapy-induced apoptosis but does not enhance long-term survival in clonogenic assays (128).
What could explain these discrepancies? Though it is possible that apoptosis does not contribute to treatment sensitivity in solid tumors, some caveats are worth mentioning. First, clinical studies typically examine single alterations (e.g. p53 mutation) relying on detection methods that are not perfect and cannot exclude extragenic mutations in the same pathway tumors would be mistakenly classified as 'p53 normal' by current technologies. Secondly, while clonogenic survival is often considered the 'gold-standard' of cytotoxicity assays, in the 1970s pathologists noticed that radiation and chemotherthis readout does not always reflect the in vivo response (129) . apy can induce cell death with morphological features of It is possible that extracellular survival factors-influenced by apoptosis (112) (Figure 2 ), although the significance of these cell density or microenvironment-can affect drug-induced observations was not widely appreciated. In particular, the death (130). premise that anticancer agents induce apoptotic cell death Anticancer agents induce apoptosis in normal tissues as well implies that cellular responses occurring after the drug-target as in tumors. In fact, many of the pathologists who identified interaction can have impact on drug-induced cell death (113- apoptosis in tumors realized that apoptotic cell death was 115).
induced in a subset of normal tissues (e.g. bone marrow and It is now well-established that anticancer agents induce intestine), and it was suggested that the process might contribapoptosis, and that disruption of apoptotic programs can reduce ute to the 'toxicity' associated with chemotherapy (112) . treatment sensitivity (116) . Since agents with distinct primary Studies using mouse models provide strong support for this targets can induce apoptosis through similar mechanisms, idea. For example, moderate doses of radiation and chemothermutations in apoptotic programs produce multi-drug resistance apy induce apoptosis in the murine thymus, spleen, bone (113, 117) . For example, many agents activate p53, and that marrow and intestine, the same tissues that account for the p53 loss can attenuate drug-induced cell death (15) . Moreover, deleterious side-effects of chemotherapy. However, these tisp53 mutations reduce therapy-induced apoptosis and tumor sues in p53 'knockout' mice display much reduced apoptosis regression in experimentally generated and spontaneous murine and cell loss following radiation or chemotherapy (17,18,131-tumors (102,118), whereas re-introduction of normal p53 to 134), and these animals are resistant to otherwise lethal doses p53 mutant tumor lines and xenographs cooperates with of ionizing radiation (135). Similarly, ectopic expression of chemotherapy to induce apoptosis and tumor regression Bcl-2 in bone marrow cells achieves a similar effect (136). (15, 119) . p53 is not strictly required for drug-induced cell Together, these studies strongly suggest that drug-induced death; indeed, at sufficient doses virtually all anticancer agents apoptosis causes loss of normal cells and contributes to the induce apoptosis (and other types of death) independently of side effects of cancer therapy. p53 (15) . In fact, the contribution of p53 to drug-induced apoptosis is determined by a variety of factors, including agent, dose, tissue and mutational background of the tumor Apoptosis: a biological link between cancer genetics and (15, 120, 121) . In short-term assays, Bcl-2 can promote resistcancer therapy ance to a wide range of anticancer agents (122, 123 ) and can The studies described above highlight the fact that disruption even prevent p53-independent deaths (124). Because Bcl-2 is of apoptosis can promote tumor initiation, progression and considered as a general apoptosis inhibitor, these results argue treatment resistance. Indeed, it is remarkable that the same for the broad importance of apoptosis in treatment sensitivity.
genetic alterations that influence apoptosis during tumoriAdditionally, death receptor pathways may also contribute to genesis also modulate treatment sensitivity. For example, therapy-induced apoptosis (125), although the relative contribuc-Myc enhances apoptosis in low concentrations of survival tion of these effects is controversial (126).
factors or oxygen and following treatment with diverse In human cancer, the most compelling links between cytotoxic agents (38,82,137), conversely, loss of p53 and apoptosis and treatment sensitivity occur in patients with overexpression of Bcl-2 suppress apoptosis induced by oncoleukemia or lymphoma. In these malignancies, p53 mutations genes, depletion of survival factors, hypoxia and cytotoxic correlate with short remissions and drug resistance following drugs (17,118,138). As a result, anti-apoptotic mutations arising therapy (15) . Also, INK4a/ARF mutations, which reduce cycloduring the course of tumor development can simultaneously phosphamide-induced death in murine lymphomas (102) , are select for chemoresistant cells. This pattern of co-selection associated with poor treatment outcome in acute lymphoblastic leukemia (127). The extent to which apoptosis contributes to may explain the phenomenon of de novo drug resistance, i.e.
tumors that initially respond poorly to therapy despite having feasible. First, most anti-apoptotic mutations act relatively upstream in the program (e.g. PTEN and p53 loss; Ras never been selected in the presence of drug.
Studies on c-Myc-induced lymphomagenesis support and NF-κB activation), implying that tumor cells retain the 'machinery' and latent potential for apoptosis. Secondly, tumordirectly link disruption of apoptosis during tumor development to de novo resistance (102) . In a mouse lymphoma model, specific alterations in apoptotic programs provide opportunities to target cell death in a selective manner. Several current INK4a/ARF or p53 mutations dramatically accelerate c-Mycinduced lymphomagenesis, owing to a defect in oncogenestrategies are discussed below. induced apoptosis. Moreover, these tumors respond poorly to
Targeting anti-apoptotic activities therapy; whereas mice harboring tumors with an intact p53
In instances where apoptosis is disabled by dominant oncopathway are cured, the vast majority harboring tumors with genes, agents that disrupt their anti-apoptotic function can INK4a/ARF or p53 mutations relapse shortly after treatment.
produce remarkable increases in cell death. Overexpression of This pattern of 'resistance' is particularly common in advanced anti-apoptotic Bcl-2 family members can promote tumorigensolid tumors. These tumor-types probably encounter many esis and chemoresistance, suggesting that functional inhibition 'triggers' of apoptosis during tumor evolution (e.g. survival of these proteins might be lethal to cancer cells. Indeed, factor depletion, hypoxia, loss of cell-matrix interactions), and adenoviral gene transfer of Bax results in cytotoxicity in it seems likely that one or more apoptotic programs must be human ovarian cancer cell lines, and administration of Adlost to reach the malignant state. Perhaps this explains why DF3-Bax following tumor inoculation eradicated Ͼ99% of many advanced solid tumors are inherently difficult to treat.
tumor implants in nude mice (146). Adenovirus-mediated gene transfer of Bcl-x S , a dominant-negative repressor of Bcl-2 and Non-apoptotic forms of 'programmed cell death ' Bcl-x L , can synergize with chemotherapy and promote tumor Although apoptosis is a cell death program, not all programmed regression in xenographs (147,148), but produces minimal 'deaths' are apoptotic. In addition to cell death, other proapoptosis when introduced into normal epithelial cells (149) . grammed responses contribute to the deletion of potentially Some current anticancer agents may unwittingly target the cancerous cells. Senescence is an irreversible program of cellBcl-2 family; for example, taxanes may induce phosphorylation cycle arrest that is disrupted in many tumors or tumor-derived and inactivation of Bcl-2 (150). As more is learned about lines (139) . Replicative senescence was originally defined by Bcl-2 structure and function, small molecule inhibitors of Bclthe observation that primary cells have a genetically determined 2 action might become feasible. limit to their proliferative potential in cell culture, after which Hyperactivation of cell survival signaling may accompany they permanently arrest with characteristic features. Owing to tumor development, and these pathways are particularly excitthe 'end-replication problem', telomeres shorten during each ing targets for small molecule inhibition. NF-κB activity can cell division unless telomerase is expressed, and it is thought be induced by oncogenes or anticancer agents to promote cell that some aspect of excessive telomere shortening activates survival, such that inactivating NF-κB enhances cell death in cell-cycle arrest and other characteristics of senescence (139) .
response to tumor necrosis factor and certain chemotherapeutic However, other stimuli can induce phenotypes suggestive agents (151) . In fact, inhibiting NF-κB activity using I-κB or of senescence, including mitogenic oncogenes and ionizing proteosome inhibitors synergizes with radiation and chemotherradiation (140-143).
apy to induce cell death in tumor lines and xenographs These observations imply that cellular senescence can be (152,153). The PI-3 kinase/Akt pathway involves a series of induced by diverse stimuli leading to the engagement of a enzymes that transit the survival signals. In principle, small common cell-cycle arrest program. In this view, senescence is molecule inhibition of any of these molecules might restore conceptually similar to apoptosis, which is induced by diverse apoptosis to tumor cells, or synergize with more classic agents stimuli leading to the engagement of a common cell death to induce cell death (154) . program. Consequently, the biological roles of cellular senesOncogenic ras mutations deregulate normal growth control cence may go beyond the control of cellular or organismal but can also signal cell survival (34) . Therefore, agents that aging, and reflect a global anti-proliferative response to a interfere with Ras function might be cytostatic or cytotoxic. variety of cellular stresses. In this view, senescence may
To be biologically active, Ras must be modified by a represent an important form of programmed cellular 'death' farnysltransferase, and many groups have developed that limits tumor development. Recent evidence suggests that farnysltransferase inhibitors as anti-tumor agents. Although anticancer agents induce cellular senescence in human tumorthese agents were predicted to be cytostatic, they can induce derived lines treated in culture or as xenographs (144,145).
massive apoptosis and tumor regression of mammary carcinTogether, the non-apoptotic forms of 'programmed cell death', omas arising in ras transgenic mice (120) . In addition, inhibisuch as senescence, might also be important for therapy.
tion of Ras-GAP induces apoptosis specifically in tumor, but not in normal cells, suggesting Ras-GAP as a novel target for cancer therapy (155). Why would these agents induce apoptosis Apoptosis and new therapeutic strategies and, moreover, why would they be selective? The answer is Since apoptotic programs can be manipulated to produce unknown, but it is possible that tumor cells become dependent massive changes in cell death, the genes and proteins controlon survival signaling through the PI-3 kinase pathway, which ling apoptosis are potential drug targets. As indicated above, could be suppressed by Ras inhibition. many empirically derived cytotoxic drugs already may target
Restoring pro-apoptotic activities apoptosis, albeit indirectly and non-exclusively. They are also mutagenic and toxic to normal tissues. In contrast, agents that
In circumstances where apoptosis is lost by a recessive mutation, restoring the dysfunctional gene or activity can directly induce apoptosis may provide less opportunity for acquired drug resistance, decrease mutagenesis and reduce promote massive cell death. For example, reintroduction of p53 into p53 mutant tumor cells can directly induce apoptosis toxicity. Two observations suggest that such strategies are or enhance treatment sensitivity in tumor cell lines or in that simultaneous inactivation of Rb and cdk2 would be xenographs (156, 157) . Indeed, strategies using this approach particularly pro-apoptotic, and produce a synthetic lethal effect are currently in clinical trials (158) . As a general rule, tumor in cells with a mutant Rb pathway (168). Consistent with this cells are inherently more sensitive to p53 inhibition than hypothesis, cell-permeable peptides that interfere with cdk2 normal cells, perhaps because mitogenic oncogenes can activate activity readily induce apoptosis in tumor cells while having p53 to promote apoptosis (117) . Hence, there is some rationale little effect on normal cell lines (168). Interestingly, although for selectivity of this approach. Of note, strategies to counter E2F-induced apoptosis is potentiated by p53 (91), these peprecessive anti-apoptotic mutations need not rely on gene or tides can induce apoptosis in p53-deficient tumor cell lines. protein therapy. In some instances, inactivation of a proTherefore, this strategy has widespread potential. apoptotic gene might actually promote cell survival by relieving Chemoprotection inhibition of a downstream death suppressor (e.g. PTEN loss
As indicated above, the propensity of certain tissues (e.g. bone de-represses Akt). In such instances, the downstream effector marrow and intestine) to drug-induced apoptosis may limit the may be a more suitable drug target (154) . effectiveness of many current therapies. Studies using mouse Death ligands models have clearly documented the importance of p53 for Although mutations in death receptors are rare events in human apoptosis in thymocytes, bone marrow and intestinal stem tumors, changes accompanying tumorigenesis can alter the cells (see above); consequently, agents which suppress p53 regulation of these pathways. Mitogenic oncogenes like c-myc function may be effective radio-or chemoprotective agents and E1A can increase sensitivity to Fas and TNF-α in cultured and/or allow dose intensification of current regimens. Since cells (159,160), and many human tumors have alterations in most advanced solid tumors have lost p53 function, these TRAIL-mediated death pathways (19). TRAIL is a TNFinhibitors should not interfere with cell death of most tumor related protein that initiates p53-independent apoptosis by cells. Recently, a small molecule (designated pifithrin-α) has binding to its receptors DR4 or DR5. Normal cells are resistant been identified that inhibits p53-mediated transcriptional to TRAIL-induced apoptosis, apparently because these cells responses and p53-induced apoptosis in cultured cells (169). express 'decoy' receptors that compete with DR4 and DR5 for
In mice, pifithrin-α is a potent radioprotective agent; pifithrin-TRAIL but do not transmit a death-inducing signal (161,162).
α treated mice survive otherwise lethal doses of ionizing Through an unknown mechanism, the expression of the decoy radiation. receptor 1 seems to be widely lost on tumor cells, making Several caveats exist with respect to p53 inhibition in them exquisitely susceptible to TRAIL-mediated cell death.
patients. First, the premise is based on animal studies, and it Because DR5 is a p53-responsive gene, combination therapy
is not yet known the extent to which p53 contributes to with TRAIL and classic cytotoxic agents may be particularly anticancer agent toxicity in humans. Secondly, although the effective in treating tumors with functional p53 (73) .
protective effects in mice are striking, the magnitude of the A conceptually related strategy for selective tumor-cell protective effect over repeated doses and time is unknown. killing involves a viral protein known as 'apoptin', the VP3 Thirdly, p53 inhibition may promote mutations by allowing product of chicken anemia virus (CAV). This protein is the survival of mutated cells. This is clearly a concern, since responsible for the cytopathic effects of CAV (163) and induces p53 'knockout' mice are extremely sensitive to radiationapoptosis in tumor cells but not normal cells (164). Although induced carcinogenesis. However, transient inhibition of p53 its mechanism of action remains unknown, apoptin-induced may be less mutagenic (169). In any case, most current apoptosis is independent of p53 and is enhanced by Bcl-2 anticancer agents are directly mutagenic, and it is not clear (165, 166) . At the very least, the remarkable effects of apoptin whether p53 inhibitors (which would only indirectly promote underscore the point that selective induction of apoptosis in mutations) would be worse. At the very least, this strategy tumor cells is achievable.
warrants further consideration. Enhancing the effects of pro-apoptotic mutations Basic studies suggest that it is possible to directly harness the Conclusion pro-apoptotic forces produced by certain oncogenic mutations to selectively kill tumor cells. As mentioned earlier, oncogenes
The last decade has seen an extraordinary increase in our like c-myc and inactivation of tumor suppressors such as Rb understanding of apoptosis, and its contribution to cancer and force proliferation but at the same time promote apoptosis, cancer therapy. Furthermore, the molecular mechanisms that presumably as a cellular safe-guard against tumorigenesis. In control and execute apoptotic cell death are coming into focus. normal cells, E1A promotes apoptosis and enhances chemosenAlthough there is much more to learn, our current understanding sitivity through a dual mechanism that involves inactivation of apoptosis provides new avenues for cancer diagnostics, of the retinoblastoma protein and binding the p300/CBP prognosis and therapy. In the coming years, it seems likely transcription co-activators. As a result, E1A mutants unable that rational strategies to manipulate cell suicide programs will to bind Rb (but retaining the p300/CBP interaction) promote produce new therapies that are less toxic and mutagenic than apoptosis in Rb-deficient cells but not normal cells (87). In current treatment regimens. principle, these E1A mutants, or small molecules which mimic their action, may provide tumor-specific anticancer agents by exploiting the fact that the Rb pathway is disrupted in the
